New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Scientists solve 18-year-old mystery and find the once-elusive source of a critical T cell population

Scientists solve 18-year-old mystery and find the once-elusive source of a critical T cell population

by Delthia Ricks , Medical XpressPresence of Tcf7+CD8+T cells during the primary response to infection. (A) Experimental schematic: Naïve P14 cells (CD45.2) were transferred into congenica
Immunology & Rheumatology January 26,2024
Scientists solve 18-year-old mystery and find the once-elusive source of a critical T cell population

Scientists solve 18-year-old mystery and find the once-elusive source of a critical T cell population

by Delthia Ricks , Medical XpressPresence of Tcf7+CD8+T cells during the primary response to infection. (A) Experimental schematic: Naïve P14 cells (CD45.2) were transferred into congenica
Immunology & Rheumatology January 26,2024
HIV: Thwarting a protein in the hope of a better quality of life

HIV: Thwarting a protein in the hope of a better quality of life

by Bruno Geoffroy, University of Montreal Hospital Research Centre (CRCHUM)Credit: Pixabay/CC0 Public DomainTo mark the occasion of World AIDS Day, Dr. Madeleine Durand and Andrés Finzi are working to
Dermatology January 26,2024
HIV: Thwarting a protein in the hope of a better quality of life

HIV: Thwarting a protein in the hope of a better quality of life

by Bruno Geoffroy, University of Montreal Hospital Research Centre (CRCHUM)Credit: Pixabay/CC0 Public DomainTo mark the occasion of World AIDS Day, Dr. Madeleine Durand and Andrés Finzi are working to
Dermatology January 26,2024
Clinical trial shows efficacy for atezolizumab combined with carboplatin

Clinical trial shows efficacy for atezolizumab combined with carboplatin

byVanderbilt University Medical CenterCredit: CC0 Public DomainImmunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastati
Oncology January 26,2024
Clinical trial shows efficacy for atezolizumab combined with carboplatin

Clinical trial shows efficacy for atezolizumab combined with carboplatin

byVanderbilt University Medical CenterCredit: CC0 Public DomainImmunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastati
Oncology January 26,2024
Immunotherapy in first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer

Immunotherapy in first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer

byVall d'Hebron Institute of OncologyCredit: CC0 Public DomainPublished inThe Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030
Oncology January 26,2024
Immunotherapy in first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer

Immunotherapy in first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer

byVall d'Hebron Institute of OncologyCredit: CC0 Public DomainPublished inThe Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030
Oncology January 26,2024
How the immune system fights to keep herpes at bay

How the immune system fights to keep herpes at bay

by Jake Miller,Harvard Medical SchoolThese microscope images show how interferon in the nucleus raises levels of the protective protein IFI16 (stained green) from low background levels (left) to
Public Health & Prevention January 26,2024
How the immune system fights to keep herpes at bay

How the immune system fights to keep herpes at bay

by Jake Miller,Harvard Medical SchoolThese microscope images show how interferon in the nucleus raises levels of the protective protein IFI16 (stained green) from low background levels (left) to
Public Health & Prevention January 26,2024
Minimizing immunotherapy's potentially harmful side effects

Minimizing immunotherapy's potentially harmful side effects

byUniversity of Miami Leonard M. Miller School of MedicineCredit: Pixabay/CC0 Public DomainRecent advances in treating multiple myeloma, the second most common blood cancer, and other blood mali
Oncology January 25,2024
Minimizing immunotherapy's potentially harmful side effects

Minimizing immunotherapy's potentially harmful side effects

byUniversity of Miami Leonard M. Miller School of MedicineCredit: Pixabay/CC0 Public DomainRecent advances in treating multiple myeloma, the second most common blood cancer, and other blood mali
Oncology January 25,2024
This gross mixture has big benefits for the study of bacteria

This gross mixture has big benefits for the study of bacteria

byUniversity of MichiganDetermining the bottleneck of infection forP. mirabilisduring UTI. (A–C) CBA/J mice were transurethrally inoculated with 107CFU. The inoculum contained
Immunology & Rheumatology January 25,2024
This gross mixture has big benefits for the study of bacteria

This gross mixture has big benefits for the study of bacteria

byUniversity of MichiganDetermining the bottleneck of infection forP. mirabilisduring UTI. (A–C) CBA/J mice were transurethrally inoculated with 107CFU. The inoculum contained
Immunology & Rheumatology January 25,2024
Hope for autoimmune skin disorder sufferers with new immunotherapy strategy

Hope for autoimmune skin disorder sufferers with new immunotherapy strategy

byThe Peter Doherty Institute for Infection and ImmunityCredit: Estzer Miller on PixabayBreakthrough research has revealed new ways to remove immune cells that cause skin autoimmune diseases wit
Immunology & Rheumatology January 25,2024
Hope for autoimmune skin disorder sufferers with new immunotherapy strategy

Hope for autoimmune skin disorder sufferers with new immunotherapy strategy

byThe Peter Doherty Institute for Infection and ImmunityCredit: Estzer Miller on PixabayBreakthrough research has revealed new ways to remove immune cells that cause skin autoimmune diseases wit
Immunology & Rheumatology January 25,2024
Identifying new potential in cancer-killing T cells

Identifying new potential in cancer-killing T cells

by Kate Ledger,Mayo ClinicGraphical illustration of a general role of ME1 in resilient CD8+T cells. Credit:Science Advances(2023). DOI: 10.1126/sciadv.adi2414When Joanina Gicob
Oncology January 25,2024
Identifying new potential in cancer-killing T cells

Identifying new potential in cancer-killing T cells

by Kate Ledger,Mayo ClinicGraphical illustration of a general role of ME1 in resilient CD8+T cells. Credit:Science Advances(2023). DOI: 10.1126/sciadv.adi2414When Joanina Gicob
Oncology January 25,2024
Collaborative study shows CAR-T cell therapy safe, effective even for high-risk patients

Collaborative study shows CAR-T cell therapy safe, effective even for high-risk patients

byUniversity of Miami Leonard M. Miller School of MedicineCredit: Pixabay/CC0 Public DomainCAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL), even fo
Oncology January 25,2024
Collaborative study shows CAR-T cell therapy safe, effective even for high-risk patients

Collaborative study shows CAR-T cell therapy safe, effective even for high-risk patients

byUniversity of Miami Leonard M. Miller School of MedicineCredit: Pixabay/CC0 Public DomainCAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL), even fo
Oncology January 25,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com